anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Telomeres, the safeguarding caps at the tips of chromosomes, are pivotal in the aging process of cells and have been linked to skin ailments and inflammatory conditions. Telomeres undergo a gradual reduction in length and factors such as oxidative stress hasten this diminishing process. Skin diseases including inflammatory conditions can be correlated with the shortening of telomeres and the persistent activation of DNA damage response in skin tissues. Telomere dysfunction could disrupt the balance of the skin, impairs wound healing, and may contribute to abnormal cytokine production. Skin aging and processes related to telomeres may function as one of the triggers for skin diseases. The presence of proinflammatory cytokines and dysfunctional telomeres in conditions such as Dyskeratosis Congenita implies a possible connection between the shortening of telomeres and the onset of chronic inflammatory skin disorders. In autoinflammatory skin diseases, chronic inflammation hinders wound healing thus aggravating the progression of the disease. The NF-ĸB pathway might contribute to the initiation or progression of chronic disorders by influencing mechanisms associated with telomere biology. The intricate connections between telomeres, telomerase, telomere-associated proteins, and skin diseases are still a complex puzzle to be solved. Here, we provide an overview of the impact of telomeres on both health and disease with a specific emphasis on their role in skin, inflammation and autoinflammatory skin disorders.
PCT No. PCT/FR91/00232 Sec. 371 Date Sep. 16, 1992 Sec. 102(e) Date Sep. 16, 1992 PCT Filed Mar. 22, 1991 PCT Pub. No. WO91/14729 PCT Pub. Date Oct. 3, 1991.The present invention relates to a film-forming product for coating solid forms, to a process for the manufacture of this film-forming product and to products coated with this film-forming product. According to the invention, this film-forming product takes the form of homogeneous granular particles which can easily be dispersed in an aqueous or organic solvent and which make it possible to obtain a uniform non-matt film, and its dry matter comprises: at least one ingestible, non-toxic film-forming substance in an amount of between 30 and 95% by weight; at least one colored pigment in an amount of between 5 and 50% by weight; and if appropriate, at least one edible plasticizer in an amount less than or equal to 30% by weight.
The main objective of this study is to evaluate the influence of exosomes derived from endothelial progenitor cells (EPC-Exo) on neointimal formation induced by balloon injury in rats. Furthermore, the study aims to investigate the potential of EPC-Exo to promote proliferation, migration, and anti-apoptotic effects of vascular endothelial cells (VECs) in vitro. The underlying mechanisms responsible for these observed effects will also be thoroughly explored and analyzed. Endothelial progenitor cells (EPCs) was isolated aseptically from Sprague-Dawley (SD) rats and cultured in complete medium. The cells were then identified using immunofluorescence and flow cytometry. The EPC-Exo were isolated and confirmed the identities by western-blot, transmission electron microscope, and nanoparticle analysis. The effects of EPC-Exo on the rat carotid artery balloon injury (BI) were detected by hematoxylin and eosin (H&E) staining, ELISA, immunohistochemistry, immunofluorescence, western-blot and qPCR. LPS was used to establish an oxidative damage model of VECs. The mechanism of EPC-Exo repairing injured vascular endothelial cells was detected by measuring the proliferation, migration, and tube function of VECs, actin cytoskeleton staining, TUNEL staining, immunofluorescence, western-blot and qPCR. In vivo, EPC-Exo exhibit inhibitory effects on neointima formation following carotid artery injury and reduce the levels of inflammatory factors, including TNF-α and IL-6. Additionally, EPC-Exo downregulate the expression of adhesion molecules on the injured vascular wall. Notably, EPC-Exo can adhere to the injured vascular area, promoting enhanced endothelial function and inhibiting vascular endothelial hyperplasia Moreover, they regulate the expression of proteins and genes associated with apoptosis, including B-cell lymphoma-2 (Bcl2), Bcl2-associated x (Bax), and Caspase-3. In vitro, experiments further confirmed that EPC-Exo treatment significantly enhances the proliferation, migration, and tube formation of VECs. Furthermore, EPC-Exo effectively attenuate lipopolysaccharides (LPS)-induced apoptosis of VECs and regulate the Bcl2/Bax/Caspase-3 signaling pathway. This study demonstrates that exosomes derived from EPCs have the ability to inhibit excessive carotid intimal hyperplasia after BI, promote the repair of endothelial cells in the area of intimal injury, and enhance endothelial function. The underlying mechanism involves the suppression of inflammation and anti-apoptotic effects. The fundamental mechanism for this anti-apoptotic effect involves the regulation of the Bcl2/Bax/Caspase-3 signaling pathway.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to technology of preparing medicinal agents containing bacterial preparations. Invention proposes method of preparing micro-capsulated forms of microorganisms using copolymer of acrylic and methacrylic acid in the form of an aqueous suspension. Paraffins, mineral and vegetable oils are used as an external phase. EFFECT: enhanced ecological purity, decreased fire hazard of process. 3 ex
Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
The present invention provides novel expression vectors which permit tight regulation of gene expression in eucaryotic cells. More specifically, the invention provides DNA vectors comprising nucleotide sequences that are transcribed to form RNA molecules which are then replicated by a temperature-sensitive replicase to form additional RNA molecules. The RNA molecules produced by replication contain a nucleotide sequence which may be translated to produce a protein of interest or which encode one or more untranslated RNA  molecules. Also provided are methods for producing heterologous proteins and untranslated RNA molecules. Further provided are methods for administering heterologous proteins and untranslated RNA molecules to individuals. In addition, pharmaceutical compositions are provided comprising the DNA and RNA  molecules of the invention and a pharmaceutically acceptable carrier.
PURPOSE:To obtain a carcinostatic agent having an increased activity and a reduced side effect by using a conjugate of 5-fluorouracil with polygalactosamine or N-acetylated polygalactosamine as a component. CONSTITUTION:An alpha-1,4-polygalactosamine (hereinafter referred to as PG)5- fluorouracil (hereinafter referred to as 5FU) conjugate prepared by chemically bonding PG and/or at least partially N-acetylated PG with 5FU through a spacer. When PG is used, the synthesis is performed by conjugating it with 5FU by the formation of a carbamoyl bond through the amine group. When N-acetylated PG is used, the synthesis is performed by conjugating it with 5FU by the formation of a urethane bond through the methylol group. When the partially N-acetylated PG is used, a mixture of the above two conjugates is obtained. This agent can be administered not only orally but also parenterally through, for example, a hypodermic, intracutaneous, intramuscular, intraperitoneal or intraintestinal route.
PURPOSE:To obtain the titled factor in a remarkably increased production, by bringing normal diploid cells having the ability to produce the aimed plasminogen activating factor derived from humans into contact with a solution containing peptone derived from plants, and cultivating the cells. CONSTITUTION:Normal diploid cells derived from humans, e.g. human kidney, intestines, lung, heart, ureter, skin or cells derived from the whole fetus, are brought into contact with a solution containing peptone derived from plants, e.g. obtained by hydrolyzing soybean oil or cottonseed oil with a poteolytic enzyme, and cultivated to give the aimed tissual plasminogen activating factor. The above-mentiond factor is used as a thrombolytic agent and further a drug for bonding to a material, e.g. artificial blood vessels or artificial internal organs, etc. and preventing the thrombus formation or as a diagnostic agent for thrombosis, etc. EFFECT:The production is increased to several - several tens of times that of the tissual cultivation method without problems, e.g. a large amount of healthy human urine is required, etc.
FIELD: agriculture. ^ SUBSTANCE: invention relates to stabilised fodder premix or composition analogous to fodder, which has increased storage term conditioned by reduction of products of active ingredient degradation due to control of amount of stabiliser already present in composition. Fodder premix includes: a) from 0.04 to 5 % (wt/wt) of at least one avermectin or milbemicin; b) pharmaceutically acceptable excipient including: i) from 5 to 15% (wt/wt) of SAS selected from group consisting of polyoxyl-40 hydrogenated castor oil, PEG-60 of corn glyceride, PEG-60 of almond oil, PEG-40 of palm seed oil and PEG-60 of corn oil; ii) from 5 to 25% (wt/wt) of wax selected from group consisting of distilled monoglycerides, glyceryl tribehenate, glyceryl trimyristate and hydrogenated coconut glycerides; iii) from 0.1 to 2% (wt/wt) of antioxidant selected from group consisting of butylated hydroxyanisole, butylated hydroxy toluol, ascorbic acid, sodium methyl bisulfite, propyl gallate, sodium thiosulfate, propylene glycol, citric acid, water-free citric acid and their mixture; iv) from 60 to 80% (wt/wt) of pharmaceutically acceptable carrier selected from group consisting of finely crushed corncobs, corn flour, citrus flour, fermentation remnants, crushed oyster shells, bran of wheat of coarse grinding, soluble components of molasses, grinded nutrient beans, soy-bean flour, crushed limestone and dry grains; c) from 0.3 to 1.5% (wt/wt) of additional quantity of pharmaceutically acceptable acidic stabiliser in amount efficient for reduction of acid- or base-catalised degradation of at least one avermectin or milbemicin, and d) optionally, efficient amount of at least one compound, regulating insect growth. Invention also relates to method of increasing term of storage of stabilised premix or analogous to fodder composition. ^ EFFECT: invention allows to increase premix storage terms by reducing or preventing active ingredient degradation. ^ 24 cl, 4 tbl, 1 ex, 5 dwg
Sterile injectable saline will be administered subcutaneously at 0.01 mL/kg. Patients will receive 3 injections per week every other day for a total of 2 weeks or until discharge from the ICU.
ALI/ARDS is a life-threatening condition that involves inflammation of the lungs and fluid accumulation in the air sacs, which leads to low blood oxygen levels and respiratory failure. Common causes include pneumonia, sepsis, and lung trauma. Symptoms, including breathing difficulty, low blood pressure, and organ failure, usually develop within 24 to 48 hours of the original injury or illness. Most patients require immediate care in an intensive care unit, and the main form of treatment is mechanical ventilation, which delivers oxygen and a continuous level of pressure to the damaged lungs. Although progress has been made in understanding how ALI/ARDS develops, it is still unknown why recovery outcomes differ among people. Differences in the genetic basis of protein C and fibrinolysis pathways, which both play a role in preventing blood clots, may be a factor in determining the severity of and recovery from ALI. The purpose of this study is to analyze plasma and DNA from children with ALI/ARDS to identify biomarkers and genetic variations that may be related to clinical outcomes.

This study will enroll children who are hospitalized with ALI/ARDS. Participants' medical records will be reviewed to gather information about symptoms, physical exam findings, mechanical ventilator settings, and laboratory test results. A blood collection will occur on Days 1 and 3. Study researchers will analyze plasma biomarkers and use high throughput DNA sequencing technology to analyze participants' DNA.
The main limitation to increased rates of lung transplantation (LT) continues to be the availability of suitable donors. At present, the largest source of lung allografts is still donation after the neurologic determination of death (brain-death donors, DBD). However, only 20% of these donors provide acceptable lung allografts for transplantation. One of the proposed strategies to increase the lung donor pool is the use of donors after circulatory-determination-of-death (DCD), which has the potential to significantly alleviate the shortage of transplantable lungs. According to the Maastricht classification, there are five types of DCD donors. The first two categories are uncontrolled DCD donors (uDCD); the other three are controlled DCD donors (cDCD). Clinical experience with uncontrolled DCD donors is scarce and remains limited to small case series. Controlled DCD donation, meanwhile, is the most accepted type of DCD donation for lungs. Although the DCD donor pool has significantly increased, it is still underutilized worldwide. To achieve a high retrieval rate, experience with DCD donation, adequate management of the potential DCD donor at the intensive care unit (ICU), and expertise in combined organ procurement are critical. This review presents a concise update of lung donation after circulatory-determination-of-death and includes a step-by-step protocol of lung procurement using abdominal normothermic regional perfusion.
PURPOSE:To obtain a preventive agent against twitch complicated with laser arterioplasty containing nipradilol as an active ingredient. CONSTITUTION:The objective substance obtained by containing nipradilol, one of racemic modifications thereof, one of optical isomers or a mixture thereof, preferably (2'R).(3R)-nipradilol as an active ingredient, suitably blending the active ingredient with normally used pharmaceutical raw materials and preparing a pharmaceutical according to a conventional method. The preventive agent is preferably intravenously administered; however, the agent can be prepared into a dosage form for oral or rectal administration. The agent is administered in an amount of 0.001-100mg, preferably 0.1-10mg expressed in terms of the nipradilol 5min to 1hr before cautery. The nipradilol is a compounded of a chemical name 3,4-dihydro-8-(2'-hydroxy-3'-isopropylamino)propoxy-3-nitroxy-2H-1- benzopyran.
20 postmenopausal women who are planned to treat with erythropoietin alpha for their renal conditions will be included to the study. Sample size was calculated with proper power analysis with accepting the difference of 1 mm in endometrial thickness as a significant change. After the informed consent, endometrial thickness (mm), uterine artery and subendometrial blood flow by doppler ultrasonography (RI, S/D) will be measured. Same measurements will be repeated on the 3rd day and 30th day. Patients' age, BMI, co-morbidities, administered erythropoietin doses will be noted. No adverse effect is expected with regard to the ultrasonographic examination. Date of the patients who do not attend for the appointments for repetitive examinations and uninterpretable doppler variables due to the atrophic uterus will be noted as the missing data and will be excluded from the study. Proper statistical analysis will be done.
BROVANA (arformoterol tartrate) Inhalation Solution is supplied in a single strength (15 mcg of arformoterol, equivalent to 22 mcg of arformoterol tartrate) as 2 mL of a sterile solution in low-density polyethylene (LDPE) unit-dose vials overwrapped in foil. BROVANA Inhalation Solution is available in a shelf-carton containing 30 or 60 unit-dose vials.

NDC 27437-055-30: carton of 30 individually pouched unit-dose vials.

NDC 27437-055-60: carton of 60 individually pouched unit-dose vials.

Storage and Handling

Store BROVANA Inhalation Solution in the protective foil pouch under refrigeration at 36°-46°F (2°-8°C). Protect from light and excessive heat. An opened unit-dose vial should be used right away. Discard any unit-dose vial if the solution is not colorless. Unopened foil pouches of BROVANA Inhalation Solution can also be stored at room temperature 68°-77°F (20°-25°C) for up to 6 weeks. If stored at room temperature, discard if not used after 6 weeks or if past the expiration date, whichever is sooner.
Amblyopia, ('blunt vision' in Ancient Greek), also known as lazy eye, is a visual deficiency in an eye that is otherwise physically normal, or that is greater than would be expected from any structural abnormalities of the eye. There are unsubstantiated beliefs that it is more difficult to treat amblyopia in older age groups, that children that have already received failed amblyopia therapy do not respond to treatment and that full-time occlusion therapy may result in occlusion (disuse) amblyopia of the good eye. The aim of this study was to assess whether these beliefs are true. Materials and methods This was a prospective, interventional clinical trial of 115 consecutive cases with unilateral, severe amblyopia conducted at a tertiary referral center in Lahore, Pakistan, from January 2010 to October 2012. Eligibility criteria included an age of over three years, visual acuity in the amblyopic eye from 6/60 Snellen's or even counting fingers only, visual acuity in the sound eye of 6/6. A complete ophthalmic examination was performed by only one ophthalmologist (SI). This included examining the fixation pattern of both eyes, presence or absence of a phoria or a tropia by a cover-uncover test, fundus examination and color vision using Ishihara color plates. Any case with an organic cause for visual loss was excluded from the study after a thorough ophthalmological examination. Assessment of visual acuity of either eye for both near and distance acuity (Snellen's and ETDRS charts) refraction and Best Corrected Visual Acuity (BCVA) was performed by a trained optician who was masked to the study and patient's demographics.
A medical information system for facilitating the treatment of a patient by a clinician is provided. The medical information system may include a processor. The medical information system may include an input device readable by the processor. The medical information system may include a demographic information interface configured to allow the input of patient demographic information for the patient from the input device. The medical information system may include a medical history interface configured to allow the input of medical history information for the patient from the input device. The medical information system may include an examination interface configured to allow the input of examination information for the patient from the input device The medical information system may include a diagnosis interface configured to allow the clinician to select a diagnosis using the input device.
The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
The participants are asked during the intervention not to follow any diet. Women in the control group will be asked to continue normal physical activities and not to undertake Mindfulness therapy during the study period for 12 weeks.
The invention relates to a protein or a peptide containing or constituted by a peptide derived from peptide 18A and presen-ting the following characteristics: it is coiled in the form of an alpha helix having 5 turns, each turn bearing 3.6 amino acid resi-dues; the diameter of said helix is from about 13 .ANG. to about 16 .ANG.; the distance separating two consecutive turns of said helix be-ing from about 4 .ANG. to about 6 .ANG.; the length of the helix being from about 10 .ANG. to about 30 .ANG.; it is amphipathic; with said peptide being such that: either the amino acid in position 4 is Glu or Asp, and/or the amino acid in position 6 is Glu or Asp, and/or the amino acid in position 8 is Lys or Arg, and/or the amino acid in position 11 is Glu or Asp. This protein can form complexes with phospholipids, with said complexes being useful for the treatment of cardiovascular diseases.
Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
Simon two-stage was applied to estimate the required sample size for the study. Overall an estimated 43 patients were required and at least 12 patients achieved pathological complete response would be deemed as positive result. Patients will be provided 3 cycles induction Lorlatinib 100mg and then assessed whether patients would be eligible for radical surgery or local radiotherapy through multidisciplinary evaluation. After local intervention, patients could choose consolidation treatment of Lorlatinib for up to 2 years or adjuvant doublet chemotherapy for up to 4 cycles. Dynamic blood samples will be collected before and after induction Lorlatinib as well as consolidation treatment. The primary endpoints is pCR for patients who received radical surgery.
A brexpiprazole oral film, a manufacture method of the brexpiprazole oral film and a use of the brexpiprazole oral film are provided. The brexpiprazole oral film includes following components: one or more than one of an active drug, a film-forming material, a plasticizer, and a sweetener. The active drug is 7-{4-[4-(1- Benzothiophen4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one as shown in Formula I and/or a pharmaceutically acceptable salt thereof. Particle size distribution D90 of the active drug is ≤ 30 [mu]m. The bripiprazole oral film according to the present disclosure has a good dissolution rate, and users will not feel sandiness after the oral film dissolving in the oral cavity. The brexpiprazole oral film has a uniform appearance and good flexibility. No sedimentation occurs during the preparation of the film forming liquid, and content uniformity meets the requirements.
Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body’s defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Neomycin sulfate and polymyxin B sulfate together are considered active against the following microorganisms: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae. 

The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.